Announcements
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
- Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
- Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
- Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
- Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
- Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
- Ultragenyx lanceert Evkeeza® (evinacumab-concentraatoplossing voor infusie) in Nederland voor de behandeling van homozygote familiaire hypercholesterolemie (HoFH)
- Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
More ▼
Key statistics
As of last trade Ultragenyx Pharmaceutical Inc (UP0:DUS) traded at 41.60, -16.13% below its 52-week high of 49.60, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 40.40 |
---|---|
High | 41.60 |
Low | 40.40 |
Bid | 41.60 |
Offer | 42.00 |
Previous close | 40.40 |
Average volume | 13.67 |
---|---|
Shares outstanding | 93.54m |
Free float | 90.17m |
P/E (TTM) | -- |
Market cap | 4.11bn USD |
EPS (TTM) | -8.02 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 15:30 BST.
More ▼